Context Therapeutics has reported its fiscal year 2024 results, highlighting significant strides in cancer immunotherapy. With strategic acquisitions and a strengthened financial position, the biotech firm is poised to advance its pipeline of T cell engaging bispecific antibodies targeting solid tumors.